Jianhuang Lin

Jianhuang Lin

Auto-generated profile, based on publicly available information

Jianhuang Lin

Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
PLPingyu Liu
Pingyu Liu
FLFuming Li
Fuming Li
JLJianhuang Lin
Jianhuang Lin
TFTakeshi Fukumoto
Takeshi Fukumoto
TNTimothy Nacarelli
Timothy Nacarelli
RZRugang Zhang
Rugang Zhang

1 February 2020 in Cancer Cell
Verified
Journal Article
Closed access
SKSergey Karakashev
Sergey Karakashev
TFTakeshi Fukumoto
Takeshi Fukumoto
BZBo Zhao
Bo Zhao
JLJianhuang Lin
Jianhuang Lin
SWShuai Wu
Shuai Wu
RZRugang Zhang
Rugang Zhang

11 January 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
SWShuai Wu
Shuai Wu
TFTakeshi Fukumoto
Takeshi Fukumoto
JLJianhuang Lin
Jianhuang Lin
TNTimothy Nacarelli
Timothy Nacarelli
YWYemin Wang
Yemin Wang
RZRugang Zhang
Rugang Zhang

1 December 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
JLJianhuang Lin
Jianhuang Lin
DGDajiang Guo
Dajiang Guo
HLHeng Liu
Heng Liu
WZWei Zhou
Wei Zhou
CWChen Wang
Chen Wang
RZRugang Zhang
Rugang Zhang
The tumor immune microenvironment is influenced by the epigenetic landscape of the tumor. Here, we have identified the SETDB1–TRIM28 complex as a critical suppressor of antitumor immunity. An epigenetic CRISPR–Cas9 screen of 1,218 chromatin regulators identified TRIM28 as a suppressor of PD-L1 expression. We then revealed that expression of the SETDB1–TRIM28 complex negatively correlated with infiltration of effector CD8+ T cells. Inhibition of SETDB1–TRIM28 simultaneously upregulated PD-L1 and activated the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) innate immune response pathway to increase infiltration of CD8+ T cells. Mechanistically, SETDB1–TRIM28 inhibition led to micronuclei formation in the cytoplasm, which is known to activate the cGAS–STING pathway. Thus, SETDB1–TRIM28 inhibition bridges innate and adaptive immunity. Indeed, SETDB1 knockout enhanced the antitumor effects of immune checkpoint blockade with anti–PD-L1 in a mouse model of ovarian cancer in a cGAS-dependent manner. Our findings establish the SETDB1–TRIM28 complex as a regulator of antitumor immunity and demonstrate that its loss activates cGAS–STING innate immunity to boost the antitumor effects of immune checkpoint blockade.

19 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BZBo Zhao
Bo Zhao
PLPingyu Liu
Pingyu Liu
TFTakeshi Fukumoto
Takeshi Fukumoto
TNTimothy Nacarelli
Timothy Nacarelli
NFNail Fatkhutdinov
Nail Fatkhutdinov
RZRugang Zhang
Rugang Zhang
Cyclic cGMP-AMP synthase (cGAS) is a pattern recognition cytosolic DNA sensor that is essential for cellular senescence. cGAS promotes inflammatory senescence-associated secretory phenotype (SASP) through recognizing cytoplasmic chromatin during senescence. cGAS-mediated inflammation is essential for the antitumor effects of immune checkpoint blockade. However, the mechanism by which cGAS recognizes cytoplasmic chromatin is unknown. Here we show that topoisomerase 1-DNA covalent cleavage complex (TOP1cc) is both necessary and sufficient for cGAS-mediated cytoplasmic chromatin recognition and SASP during senescence. TOP1cc localizes to cytoplasmic chromatin and TOP1 interacts with cGAS to enhance the binding of cGAS to DNA. Retention of TOP1cc to cytoplasmic chromatin depends on its stabilization by the chromatin architecture protein HMGB2. Functionally, the HMGB2-TOP1cc-cGAS axis determines the response of orthotopically transplanted ex vivo therapy-induced senescent cells to immune checkpoint blockade in vivo. Together, these findings establish a HMGB2-TOP1cc-cGAS axis that enables cytoplasmic chromatin recognition and response to immune checkpoint blockade.

6 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BZBo Zhao
Bo Zhao
JLJianhuang Lin
Jianhuang Lin
LRLijie Rong
Lijie Rong
SWShuai Wu
Shuai Wu
ZDZhong Deng
Zhong Deng
RZRugang Zhang
Rugang Zhang
ARID1A inactivation causes mitotic defects. Paradoxically, cancers with high ARID1A mutation rates typically lack copy number alterations (CNAs). Here, we show that ARID1A inactivation causes defects in telomere cohesion, which selectively eliminates gross chromosome aberrations during mitosis. ARID1A promotes the expression of cohesin subunit STAG1 that is specifically required for telomere cohesion. ARID1A inactivation causes telomere damage that can be rescued by STAG1 expression. Colony formation capability of single cells in G2/M, but not G1 phase, is significantly reduced by ARID1A inactivation. This correlates with an increase in apoptosis and a reduction in tumor growth. Compared with ARID1A wild-type tumors, ARID1A-mutated tumors display significantly less CNAs across multiple cancer types. Together, these results show that ARID1A inactivation is selective against gross chromosome aberrations through causing defects in telomere cohesion, which reconciles the long-standing paradox between the role of ARID1A in maintaining mitotic integrity and the lack of genomic instability in ARID1A-mutated cancers.